Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France

Inclusion Criteria: All patients enrolled in the study must : * be at least 18; * be covered by Social Security * agree to be enrolled in the study (sign the informed consent after reading the information letter). In addition, the Xience V endoprothesis implantation must be performed following the LPPR indications here under : Treatment of coronary heart disease attributable to de novo lesions (reference vessel with a 2.5 to 3.5 mm) of native coronary arteries, solely in the following groups of patients : * patients with diabetes ; * lesions of small vessels (diameter \< 3 mm); * long lesions (longer than 15 mm) ; * stenosis of proximal anterior intraventricular septum . The use of the Xience V stent is limited to one per patient, except : * in case of acute occlusive dissection where three stents, maximum, may be covered ; * for the pluritroncular diabetic patient, in case a bypass is contra-indicated : a stent per artery, with a limit of three per patient, may be covered. Exclusion Criteria: * Pregnant women * Patients with: * a non cardiac vital prognosis endangered during the year following the implantation ; * less than 72 hours myocardial infarction ; * lower left ventricular ejection fraction \< 30 % ; * an allergy to the platelets antiaggregant treatment, to heparin, chrome cobalt alloy, or to the angiography contrast medium ; * a stenosis of the unprotected common trunk; * a lesion with calcifications that cannot be pre-dilated; * a thrombus that can be detected by angiography on the lesion to be treated ; * an intra-stent re-stenosis. Are also excluded : * patients having had an angioplasty with implantation of an endoprothesis on the same vessel; * patients having had an angioplasty with implantation of an endoprothesis during the 6 previous months ; * Patients unable to keep a treatment associating aspirin and thiénopyridines for at least 6 months; * Patients residing abroad or who cannot be monitored according to the modalities of the study ; * Patients unable to give on their own free will their informed consent ; On the other hand, in absence of clinical validation, the other sub-groups of at risk patients (notably bifurcation lesions and pluritroncular lesions) cannot be considered , taken alone, as indications for the use of Xience V.